Media headlines about Allena Pharmaceuticals (NASDAQ:ALNA) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Allena Pharmaceuticals earned a daily sentiment score of 0.02 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.9594137586375 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

ALNA traded up $0.38 during trading on Monday, reaching $10.78. 32,581 shares of the stock were exchanged, compared to its average volume of 44,068. The company has a market cap of $215.82 million and a price-to-earnings ratio of -2.25. Allena Pharmaceuticals has a twelve month low of $6.13 and a twelve month high of $17.56. The company has a current ratio of 29.32, a quick ratio of 29.32 and a debt-to-equity ratio of 0.15.

Allena Pharmaceuticals (NASDAQ:ALNA) last issued its earnings results on Tuesday, August 7th. The company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.02). research analysts forecast that Allena Pharmaceuticals will post -1.76 earnings per share for the current year.

A number of brokerages have recently commented on ALNA. Zacks Investment Research lowered shares of Allena Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, August 10th. Cowen reissued a “buy” rating on shares of Allena Pharmaceuticals in a research report on Wednesday, August 8th. B. Riley boosted their target price on shares of Allena Pharmaceuticals from $23.50 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. LADENBURG THALM/SH SH started coverage on shares of Allena Pharmaceuticals in a report on Thursday, August 2nd. They set a “buy” rating and a $23.00 target price on the stock. Finally, Wedbush restated an “outperform” rating and set a $38.00 target price on shares of Allena Pharmaceuticals in a report on Tuesday, July 24th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $29.14.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Recommended Story: How to Use a Moving Average for TradingĀ 

Insider Buying and Selling by Quarter for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with's FREE daily email newsletter.